Pharmacovigilance (PV) is not limited to clinical trials; it extends far beyond post-marketing surveillance (PMS)—a critical phase in ensuring the ongoing safety and efficacy of medicines once they are available to the public. Post-marketing surveillance helps detect risks that may not have been evident during clinical trials, ultimately safeguarding patient health and maintaining public trust in medicines.
What is Post-Marketing Surveillance?
Post-marketing surveillance is the continuous monitoring of medicinal products after they have been approved and marketed. It involves collecting, analysing, and evaluating data on adverse drug reactions (ADRs) and other safety concerns to identify previously unrecognized risks.
Sources of post-marketing data include:
- Spontaneous adverse event reports from healthcare professionals and patients
- Electronic health records (EHRs) and patient registries
- Pharmacy and insurance databases
- Real-world data from wearables, apps, and social media
Why Post-Marketing Surveillance is Essential
- Detecting Rare or Long-Term Adverse Effects
Clinical trials often involve a limited number of participants under controlled conditions. PMS captures rare, long-term, or population-specific adverse events that may emerge only after widespread use. - Supporting Regulatory Compliance
Regulatory authorities like the MHRA in the UK require companies to report safety information continuously. Post-marketing data informs risk management plans, safety updates, and regulatory decisions. - Protecting Patient Safety
Early identification of safety concerns enables prompt interventions such as label changes, dosage adjustments, or product recalls—minimising harm to patients. - Improving Therapeutic Outcomes
By understanding how medicines perform in real-world settings, healthcare providers can make more informed decisions, tailor treatments, and optimise patient care.
Challenges in Post-Marketing Surveillance
- Volume and Variety of Data: PMS involves handling large datasets from diverse sources, making manual processing inefficient.
- Timeliness: Delays in detecting safety signals can compromise patient safety.
- Data Quality and Consistency: Ensuring accuracy, completeness, and standardisation is critical for meaningful analysis.
Emerging technologies like AI, machine learning, and natural language processing are increasingly used to automate signal detection, prioritise cases, and predict potential risks—enhancing the effectiveness of post-marketing surveillance.
How Q&V Can Help
At Q&V, we support pharmaceutical companies in strengthening post-marketing surveillance by:
- Implementing robust PV systems for continuous monitoring and reporting
- Leveraging AI and automation to accelerate signal detection and case processing
- Ensuring compliance with MHRA and GVP guidelines
- Preparing for regulatory inspections and audits
Our expertise ensures that companies can monitor medicines proactively, protect patients, and stay compliant in an evolving regulatory environment.
Q&V is your trusted partner in post-marketing surveillance, helping you build efficient, compliant, and future-ready pharmacovigilance systems.